Kalaris Therapeutics's three largest insider shareholders as of March 23, 2026 are Vikas Sinha (See Remarks, 16.67Mn shares), Ansbert Gadicke (Director, 16.67Mn shares), Llc Elevatebio, (Director, 16.67Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Morana Jovan-Embiricos | 0 | 16,674,766 | 01 Aug, 2022 | |
| Ansbert Gadicke | 0 | 16,674,766 | 01 Aug, 2022 | |
| Llc Elevatebio, | 16,674,766 | 0 | 01 Aug, 2022 | |
| Vikas Sinha | See Remarks | 0 | 16,674,766 | 01 Aug, 2022 |
| Sciences, Inc. Gilead | 16,635,286 | 0 | 28 Jun, 2023 | |
| Juan Vera | 2,409,928 | 0 | 07 Jun, 2024 | |
| Ann M. Leen | Chief Scientific Officer | 0 | 2,288,154 | 16 Nov, 2021 |
| David Hallal | 2,143,662 | 0 | 07 Jun, 2024 | |
| Diana Brainard | Chief Executive Officer | 723,363 | 0 | 20 Nov, 2024 |
| Agustin Melian | Chief Medical Officer | 453,529 | 0 | 05 Oct, 2021 |
| Samir Chandrakant Patel | 252,000 | 100,800 | 18 Mar, 2025 | |
| Edward Miller | General Counsel | 0 | 346,348 | 11 Dec, 2024 |
| Beek Jeroen B Van | Chief Commercial Officer | 333,726 | 0 | 18 Nov, 2022 |
| Cintia Piccina | Chief Commercial Officer | 147,000 | 0 | 05 Jul, 2023 |
| David Hallal | 0 | 138,153 | 21 Oct, 2022 | |
| Ercem Atillasoy | See Remarks | 131,372 | 0 | 26 Oct, 2022 |
| Jeffrey S Bornstein | 110,197 | 0 | 07 Jun, 2024 | |
| Malcolm Brenner | 100,197 | 0 | 07 Jun, 2024 | |
| Morana Jovan-Embiricos | 100,197 | 0 | 07 Jun, 2024 | |
| Shawn Tomasello | 70,000 | 0 | 07 Jun, 2024 | |
| Vikas Sinha | See Remarks | 49,129 | 0 | 24 Feb, 2025 |
| Ann M. Leen | Chief Scientific Officer | 43,000 | 0 | 17 Aug, 2022 |
| Edward Miller | General Counsel | 6,517 | 0 | 24 Feb, 2025 |
| Matthew Feinsod | Chief Medical Officer | 4,030 | 0 | 18 Mar, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Mar, 2026 | Brett R Hagen | Common Stock | D | 1,915 | $6.72 | 0 | D | S |
| 19 Mar, 2026 | Brett R Hagen | Stock Option (Right to Buy) | A | 60,800 | $0.00 | 60,800 | D | A |
| 19 Mar, 2026 | Matthew Feinsod | Stock Option (Right to Buy) | A | 135,000 | $0.00 | 135,000 | D | A |
| 19 Mar, 2026 | Matthew Gall | Stock Option (Right to Buy) | A | 95,000 | $0.00 | 95,000 | D | A |
| 19 Mar, 2026 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 222,000 | $0.00 | 222,000 | D | A |
| 03 Nov, 2025 | Matthew Gall | Stock Option (Right to Buy) | A | 235,000 | $0.00 | 235,000 | D | A |
| 10 Apr, 2025 | Brett R Hagen | Stock Option (Right to Buy) | A | 50,262 | $0.00 | 50,262 | D | A |
| 10 Apr, 2025 | Andrew Oxtoby | Stock Option (Right to Buy) | A | 287,000 | $0.00 | 287,000 | D | A |
| 10 Apr, 2025 | Leone D Patterson | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Matthew Feinsod | Stock Option (Right to Buy) | A | 70,551 | $0.00 | 70,551 | D | A |
| 10 Apr, 2025 | Samir Chandrakant Patel | Stock Option (Right to Buy) | A | 18,000 | $0.00 | 18,000 | D | A |
| 10 Apr, 2025 | Matthew Feinsod | Stock Option (Right to Buy) | A | 101,000 | $0.00 | 101,000 | D | A |
| 26 Mar, 2025 | Brett R Hagen | Common Stock | D | 907 | $8.97 | 1,925 | D | S |
| 18 Mar, 2025 | Andrew Oxtoby | Stock Option (right to buy) | A | 476,611 | - | 476,611 | D | A |
| 18 Mar, 2025 | Samir Chandrakant Patel | Common Stock | A | 252,000 | - | 252,000 | D | A |
| 18 Mar, 2025 | Matthew Feinsod | Common Stock | A | 4,030 | - | 4,030 | D | A |
| 18 Mar, 2025 | Matthew Feinsod | Stock Option (right to buy) | A | 28,224 | - | 28,224 | D | A |
| 18 Mar, 2025 | Samir Chandrakant Patel | Common Stock | A | 100,800 | - | 100,800 | I | A |
| 18 Mar, 2025 | Samir Chandrakant Patel | Stock Option (right to buy) | A | 105,913 | - | 105,913 | D | A |
| 21 Feb, 2025 | Vikas Sinha | Common Stock | D | 303 | $10.08 | 49,129 | D | S |